Anakuria Therapeutics Inc. has identified rapamycin derivatives acting as mTOR complex 1 (mTORC1) inhibitors reported to be useful for the treatment of diabetic nephropathy, chronic obstructive pulmonary disease, epilepsy, fragile X syndrome, urinary tract infection, heart failure, glaucoma and autosomal dominant polycystic kidney, among others.

Regulatory T cells (Tregs) are contributors of tumor immune evasion; Ikaros family zinc finger protein 2 (IKZF2) plays a crucial role in the maintenance of function and stability of Tregs. IKZF2-deificent tumoral Tregs produce inflammatory cytokines and enhance antitumoral immunity in mice.

Txinno Bioscience has presented benzotriazole derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1) inhibitors reported to be useful for the treatment of cancer.

The Broad Institute, Janssen Biotech and Massachusetts General Hospital have divulged new serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Shandong University scientists have evaluated structural modification of parbendazole to derive potential treatments for head and neck squamous cell carcinoma (HNSCC).

The FDA has cleared Tachyon Therapeutics' IND application to develop TACH-101 for the treatment of advanced solid tumors.

At the ongoing American Chemical Society meeting, Genentech detailed the discovery of KRAS G12C-selective covalent inhibitors for the potential treatment of cancer.

The Universite Catholique de Louvain has described polypeptides acting as lactate dehydrogenase (LDH) tetramerization inhibitors reported to be useful for the treatment of cancer.